CD26 Expression in Mature B-cell Neoplasms and its Prognostic Impact on B-Cell Chronic Lymphocytic Leukemia
- *Corresponding Author:
- Doaa M. El Ghannam
Department of Clinical Pathology
Faculty of Medicine, Mansoura University, Egypt
E-mail: [email protected]
Received date: April 23, 2014; Accepted date: June 06, 2014; Published date: June 15, 2014
Citation: Ghannam DME, Taalab MM, Ghazy HF, Salam EMA, Fawzy IM (2014) CD26 Expression in Mature B-cell Neoplasms and its Prognostic Impact on B-Cell Chronic Lymphocytic Leukemia. J Blood Disord Transfus 5:222. doi:10.4172/2155-9864.1000222
Copyright: © 2014 Ghannam DME, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
CD26/dipeptidyl peptidase IV (DPPIV) is a multifunctional membrane protein and it is strongly upregulated in activated B-cells. We aimed to evaluate CD26 expression in mature B cell neoplasms, and its prognostic role in B cell chronic lymphocytic leukaemias (B-CLL). CD26 expression was evaluated by flow cytometry in various B cell neoplasms. CD26 expression was high in MMs and HCLs, variable in B-CLLs and in CD5neg B-CLPDs. Kaplan–Meier curves revealed a significantly shorter progression free survival (PFS), and lymphocytic doubling time (LDT) in the CD26 high expression group (p=0.014, 0.024 respectively). High CD26, CD38 and/or ZAP70 showed significantly shorter PFS, (p=0.020, 0.022 respectively) and LDT (p=0.024, 0.024 respectively) when compared to both low expression CD26, CD38 and/or ZAP70. CD26 expression may identify subsets of B-CLL patients with an unfavorable clinical outcome, thus suggesting its potential role as a marker in a future routine cytofluorimetric panel for B-CLLs.